

Nutramigen with LGG®: shown to provide long-term cost effectiveness to the NHS for the dietary management of cow's milk protein allergy (CMPA)

A new health economics study shows the cost effectiveness of Nutramigen with Lactobacillus rhamnosus (LGG®) compared to an eHCF alone as first-line dietary management for IgE-mediated CMPA.

For first line dietary management of CMPA, Nutramigen with LGG®:

Improves clinical outcomes¹



Releases NHS resources¹
e.g. Frees up NHS appointments



Reduces NHS costs¹



The unique formula of Nutramigen with LGG® is proven to deliver both short and long-term clinical outcomes. Resulting in cost effectiveness due to:


Fast symptom resolution with 99% proven average clinical efficacy^{3†}



Proven to help x4 more infants return to milk sooner^{2‡}



Proven to reduce incidence of 1 or more future allergic manifestations by ~50%²



Reductions in incidence:

- ▼ 68% rhinoconjunctivitis
- ▼ 61% allergic urticaria
- ▼ 51% asthma
- ▼ 44% eczema

Nutramigen with LGG® can save the NHS, on average:

The study estimated the total 5 year cost of initially feeding infants with eHCF with LGG® was less than that of an eHCF alone

£497
savings per infant
over 3 years¹




£907
savings per infant
over 5 years^{1*}

Incremental cost effectiveness ratio (ICER)

Nutramigen with LGG® was shown to be a cost effective strategy for up to 5 years for each additional infant who was:

- tolerant to cow's milk **-£3,240**
- symptom free **-£4,320** (no allergic manifestation)



*Projected savings over 5 years †Calculated using data on allergic reactions after oral food challenge with an eHF from table 3 of Dupont et al. 2012, as judged by the Committee on Nutrition of the French Society of Paediatrics. ‡Versus an eHCF without LGG, or formulas based on soy or amino acids.

References 1. Guest JF, Singh H Curr Med Res Opin 2019; 24:1-9 2. Canani RB et al. J Allergy Clin Immunol 2017;139:1906-1913 3. Dupont C et al. Br J Nutr. 2012;107:325-338.

eHCF = Extensively hydrolysed casein formula

IMPORTANT NOTICE: Breastfeeding is best for babies. The decision to discontinue breastfeeding may be difficult to reverse and the introduction of partial bottle-feeding may reduce breast milk supply. The financial benefits of breastfeeding should be considered before bottle-feeding is initiated. Failure to follow preparation instructions carefully may be harmful to your baby's health. Parents should always be advised by an independent healthcare professional regarding infant feeding. Products of Mead Johnson must be used under medical supervision. *Trademark of Mead Johnson & Company, LLC. © 2018 Mead Johnson & Company, LLC. All rights reserved. LGG® is a registered trademark of Chr. Hansen A/S. Nutramigen with LGG® is not recommended for premature and immunocompromised infants unless directed and supervised by a healthcare professional.

Date of preparation: August 2019 RB-M-00252

MeadJohnson
Nutrition

rb
HEALTH • HYGIENE • HOME



For long-term, cost effective dietary management of CMPA

